In this direction, a recent study by Wartenberg et al. that combined NGS analysis with immunohistochemistry proposes three subtypes with different immune characteristics: (i) immune-escaped with few tumor lymphocytes in the stroma (low expression of CD3, CD4, CD8 and increased T regulators with FOXP3), mutations in KRAS and worse prognosis; (ii) immune-rich with abundant CD4, CD8 and CD3 lymphocytes, and B cells but proportionally few FOXP3 lymphocytes. The gene discussed is KRAS; the disease is neoplasm.